Clinical Trials Logo
NCT number NCT01200875
Study type Observational
Source Stanford University
Contact Amy S Wasterlain
Phone (718) 644-5731
Email awasterl@stanford.edu
Status Recruiting
Phase N/A
Start date July 2010
Completion date July 2012

Clinical Trial Summary

Platelet-Rich Plasma (PRP) has been banned in competitive athletes because some people think it may enhance athletic performance. However, there is very little published research to support or undermine this point of view. The purposes of this study are: (1) To assess the effects of local platelet-rich plasma (PRP) therapy on systemic levels of growth factors with suspected or known performance-enhancing effects; and (2) To understand whether the effect of PRP therapy on these growth factors differs between intramuscular and intratendinous PRP injections.

This research study is looking for 40 people who are receiving platelet-rich plasma therapy for a tendon or muscle injury. The study involves collecting seven blood samples (2 teaspoons each) from each patient, before and after the PRP treatment. Blood samples may be donated at any location of the patient's choosing, and participants will be paid for their time.


Clinical Trial Description

To understand the short-term systemic effects of local PRP injections, we will measure the serum concentrations of six growth factors before and during the four days following PRP injection: human growth hormone (hGH), IGF-1, basic FGF, PDGF-BB, VEGF, and IGFBP-3. These molecules are of particular interest because they may have stimulatory effects that enhance athletic performance, and because they have been banned in competitive athletes by the World Anti-Doping Agency (WADA).

We aim to recruit 40 patients who are receiving ultrasound-guided intratendinous (IT) or intramuscular (IM) PRP injections. Blood will be drawn immediately before (baseline); 15 minutes after; and 3, 24, 48, 72 and 96 hours after receiving PRP therapy. A fraction of the therapeutic PRP preparation will be isolated for growth factor analysis. Serum concentrations of growth factors will be quantified by ELISA. Statistical analyses will be conducted to assess the change in each growth factor following PRP injection. To understand the impact of injection site on systemic growth factors, changes in concentration will also be compared between the intratendinous and intramuscular groups.

Study subjects will participate in the following steps: (1) Initial diagnostic visit with Orthopaedic Surgeon, (2) Blood collection as part of PRP therapy, (3) Ultrasound-guided PRP therapy administered by Stanford radiologist, and (4) Blood collection for the study. Steps (1) through (3) are all part of the standard of care, which the patient will have chosen independently of the study. In step (4), blood samples will be collected by venipuncture at various time points and assayed for growth factor concentrations. Less than 10 mL (2 teaspoons) of blood will be collected at each of seven time points over five consecutive days. In order to minimize inconvenience to the patient we will meet patients at a location of their choosing, such as the patient's home or office, for blood collection on days 2-5. Participants will be compensated after all seven blood samples have been donated.


Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


See also
  Status Clinical Trial Phase
Recruiting NCT03307499 - NeoPatch Used as Adjunct in Foot and Ankle Tendon Surgery N/A
Recruiting NCT02499484 - Topical Glyceryl Trinitrate (GTN) and Eccentric Exercises in the Treatment of Midportion Achilles Tendinopathy N/A
Completed NCT01944150 - Association of Transcutaneous Electrical Nerve Stimulation and Hypnosis N/A
Recruiting NCT03262181 - The Acute Effects of an Isometric Loading Intervention on Lower Extremity Landing Biomechanics in Individuals With Patellar Tendinopathy N/A
Terminated NCT01544244 - The Global Shoulder Concept (GSC) Method Versus Classic Physical Therapy for Shoulder Tendinitis N/A
Terminated NCT02978833 - Platelet-rich Plasma vs. Whole Blood for Gluteus Medius Tendinopathy Phase 4
Completed NCT03229291 - A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SM04755 Following Topical Administration to Healthy Subjects Phase 1
Recruiting NCT02981394 - Clinical Outcomes of Autologous Bone Marrow Aspirate Concentrate Injections for Musculoskeletal Conditions N/A
Recruiting NCT02600910 - Natural History of Shoulder Pathology in Manual Wheelchair Users N/A
Not yet recruiting NCT01225497 - Eccentric Exercise for Chronic Mid-portion Achilles Tendinopathy N/A
Not yet recruiting NCT02775201 - Plantaris Release for Non-insertional Achilles Tendinopathy N/A
Terminated NCT02330146 - Safety and Efficacy of RCT-01 in Men and Women With Unilateral, Chronic Achilles Tendinosis Phase 1/Phase 2
Completed NCT02417987 - High Volume Injection or Autologous Conditioned Plasma (ACP) in Chronic Achilles Tendinopathy N/A
Completed NCT03142971 - Shock Wave Therapy for Lateral Hip Pain, Caused by Tendon Pathology N/A
Completed NCT01652495 - Evaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to Corticosteroids Intrabursal Injection Phase 4
Recruiting NCT03090672 - Cellular & Biocellular Regenerative Therapy in Musculoskeletal Pain, Dysfunction,Degenerative or Inflammatory Disease N/A
Not yet recruiting NCT02597660 - A Study to Evaluate the Efficacy of Somatropin in the Treatment of Patellar Tendinopathy Phase 2
Recruiting NCT02797925 - Mechanisms Behind Development of Tendinopathy N/A
Recruiting NCT02757664 - Clinical Trial to Evaluate the Adjuvant Effect of Shock Wave Therapy in the Insertional Achilles Tendinopathy N/A
Active, not recruiting NCT02811003 - Achilles Tendon Repair With Bioinductive Implant N/A